Wegovy availability has improved in 2025 and 2026 after the FDA removed semaglutide from its active drug shortage list. Most US pharmacies can now fill prescriptions for all five approved doses, although intermittent back-orders at individual stores still happen when demand surges. Access also depends on insurance coverage and prior authorization, which often decide whether a prescription moves forward as quickly as supply allows.
Wegovy Supply Status in 2025 and 2026
Novo Nordisk scaled up manufacturing through 2023 and 2024 in response to global demand for semaglutide. By February 2025, the FDA Drug Shortages database reflected a resolution of semaglutide shortage status. That change removed the legal basis for large-scale compounding under section 503A and 503B exceptions tied to shortage. Nationwide supply has remained broadly stable since, though specific doses can be temporarily short at individual pharmacies during peak months.
When a pharmacy says Wegovy is on back-order, it is usually a local inventory issue, not a national shortage. Calling a few nearby chain or independent pharmacies, or asking your prescriber to transfer the prescription, often resolves the gap.
Approved Doses and How Availability Breaks Down
| Dose | Purpose | Typical Supply Status |
|---|---|---|
| 0.25 mg weekly | Starter, weeks 1 to 4 | High demand, sometimes tight |
| 0.5 mg weekly | Titration, weeks 5 to 8 | Generally available |
| 1 mg weekly | Titration, weeks 9 to 12 | Generally available |
| 1.7 mg weekly | Titration, weeks 13 to 16 | Generally available |
| 2.4 mg weekly | Maintenance target | Generally available |
Starter doses are often the tightest because every new patient begins there. If your 0.25 mg pen is not in stock, some prescribers may consider alternate titration schedules or an initial fill at a different pharmacy, rather than skipping to a higher dose.
How to Check If Your Pharmacy Has Wegovy
Phone the pharmacy before dropping off the prescription. Ask specifically about the strength you were prescribed, not just Wegovy in general. Some chains maintain real-time inventory through mobile apps. Independent pharmacies sometimes receive shipments on different cycles than big chains and may have stock when larger stores do not. Novo Nordisk also runs a locator tool on the Wegovy website.
Be prepared to wait a few days if the pharmacy is ordering stock. Transferring the prescription to another pharmacy is straightforward for most patients, but insurance networks may prefer specific pharmacies for coverage.
Insurance Coverage Is the Real Gatekeeper
Even when Wegovy is on the shelf, insurance coverage often decides whether you pay a reasonable copay or full list price. Many commercial plans cover Wegovy for obesity with a body mass index of 30 or above, or BMI of 27 or above with at least one weight-related condition such as hypertension or dyslipidemia. Prior authorization is common, and some plans require documented prior weight-loss attempts or participation in a lifestyle program.
Medicare Part D has historically excluded drugs used only for weight loss, although coverage has expanded for semaglutide indicated for cardiovascular risk reduction under the brand Wegovy in select patients. State Medicaid plans vary widely. Ask your clinician’s office about prior authorization support and appeals if your first submission is denied.
Wegovy vs. Compounded Semaglutide
During the earlier shortage, many patients turned to compounded semaglutide from 503A and 503B pharmacies as a legal workaround. With shortage status resolved, the FDA expects large-scale compounding of semaglutide copies to wind down. Compounded products are not FDA approved, may vary in dose and purity, and the FDA has received adverse event reports related to some products.
If you are currently on compounded semaglutide, discuss transition timelines with your clinician before supply ends. Brand Wegovy or the diabetes brand Ozempic of the same molecule remains the FDA-approved path, though access and cost considerations differ. Our overview of prediabetes treatment pages provides broader context.
What to Do If Your Dose Is Unavailable
If you cannot find your specific dose, do not double a lower dose or halve a higher dose on your own. Contact your prescriber. Options include pausing at the current dose for an extra month, switching to a different pharmacy, asking about a manufacturer savings card workaround, or discussing whether switching to a different GLP-1 receptor agonist is appropriate. Never split or modify injection pens without explicit clinician guidance.
Missing a dose for a week is usually not dangerous, but restarting after a gap of more than two weeks may call for dose reduction to avoid nausea. Your prescriber will set the safest path.
Side Effects to Watch For
Common side effects include nausea, vomiting, diarrhea, constipation, abdominal pain, and fatigue, mostly during dose escalation. Less common but serious risks include pancreatitis, gallbladder disease, and possible thyroid tumors in rodents that have prompted warnings in the label. Anyone with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 should not take Wegovy. Full prescribing information is on the Wegovy label.
Who Uses Wegovy and Why It Matters for Prediabetes
Wegovy is FDA approved for chronic weight management in adults and some adolescents with obesity or overweight with a weight-related condition. Significant weight loss improves insulin sensitivity and reduces the risk of progression from prediabetes to type 2 diabetes. In trials, patients on Wegovy lost roughly 10 to 15 percent of body weight on average, with associated improvements in blood pressure, lipids, and A1C levels.
The Bottom Line
Wegovy availability has improved since the FDA moved semaglutide off shortage status, though starter doses and individual pharmacy inventory can still fluctuate. Insurance coverage is often the bigger barrier than stock. Avoid unregulated compounded versions now that shortage has resolved, and work with your clinician to handle titration, side effects, and dose changes safely.
Medical disclaimer: This article is for educational purposes only and does not replace medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medical device or therapy.
